Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers

Proceedings of the National Academy of Sciences(2023)10.1073/pnas.2220413120Source: DataRank Database

Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers is a research paper published in Proceedings of the National Academy of Sciences (2023). On theSindex it has a DataRank of 0. It has been cited 26 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access26 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 4.18)OA: greenTopics (56)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Zachary V. Samuels ORCID,Lukas M. Carter ORCID,Sébastien Monette ORCID,Sandeep Surendra Panikar ORCID,Patrícia M. R. Pereira ORCID

Live enrichment

PubMed:36972439 PMC:PMC10083538 OpenAlex:https://openalex.org/W4360993040

HHS | National Institutes of Health

Grant: CA232130

HHS | National Institutes of Health

Grant: CA244233-01A1

NCI NIH HHS

Grant: R01 CA244233

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: R37 CA276498

NCI NIH HHS

Grant: R35 CA232130

National Institutes of Health

Grant: 5R01CA244233-03

Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin

National Institutes of Health

Grant: 3R35CA232130-03S1

Annotating Cancer Biology through Non-Invasive Molecular Imaging

National Institutes of Health

Grant: 1R37CA276498-01

Reversing Drug Resistance in Tumors with Clickable Antibody Pairs

FWCI

4.18

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

greenLicense: cc-by-nc-nd

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10083538/pdf/pnas.202220413.pdf

HYBRIDhttps://doi.org/10.1073/pnas.2220413120

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10083538/pdf/pnas.202220413.pdf

publisherhttps://pnas.org/doi/pdf/10.1073/pnas.2220413120

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10083538

Fields of Study

Radiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and AnalysisMonoclonal and Polyclonal Antibodies ResearchMedicine03 medical and health sciences0302 clinical medicineHumansAnimalsMiceStomach NeoplasmsHydroxymethylglutaryl-CoA Reductase InhibitorsPharmaceutical PreparationsErb-b2 Receptor Tyrosine KinasesTrastuzumabLovastatinCell Line, Tumor

MeSH Terms

TrastuzumabAnimalsPharmaceutical PreparationsHumansLovastatinStomach NeoplasmsReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesHydroxymethylglutaryl-CoA Reductase InhibitorsCell Line, TumorMice

Keywords

TrastuzumabMedicineTargeted therapyCancerPharmacologyOncologyCancer researchInternal medicineBreast cancerstatinsHuman Epidermal Growth Factor Receptor 2 (Her2)Radioligand TherapyTrastuzumab-resistant CancerTumorICTS (Institute of Clinical and Translational Sciences)Biological SciencesErb-b2 Receptor Tyrosine KinasesCell LineMiceErbB-2Pharmaceutical PreparationsStomach NeoplasmsCell Line, TumorMedicine and Health SciencesHumansAnimalsLovastatinHydroxymethylglutaryl-CoA Reductase InhibitorsReceptor

Sustainable Development Goals

SDG 0: Good health and well-being